RE:RE:Till we have
with the results posted in latest communication, the drug formulation is way ahead of competition and this is significant that no side effects as well like liver or kidney damage. They had to burn cash and next step is simply convincing investors to get onboard which should be relatively easy considering the numbers from trials and market value of the drug if succesfful.
10 cents is very low for this stock. This should be heading higher any time now.